SPT (1789) reported revenue of NT$163.3 million for Oct 2026, -47.4% year on year and -47.2% from the previous month. Revenue for Jan–Oct 2026 was NT$2.2 billion (-11.0% year on year).
In Oct 2026, it ranked No. 50 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$163.3 million | -47.4% | -47.2% |
| Sep 2026 | NT$309.4 million | +74.4% | +55.3% |
| Aug 2026 | NT$199.3 million | -42.2% | +7.5% |
| Jul 2026 | NT$185.4 million | -7.1% | -25.3% |
| Jun 2026 | NT$248.3 million | -3.9% | +41.7% |
| May 2026 | NT$175.2 million | -33.2% | -31.3% |
| Apr 2026 | NT$255 million | +12.5% | -21.6% |
| Mar 2026 | NT$325.2 million | +3.4% | +56.8% |
| Feb 2026 | NT$207.5 million | +26.3% | +63.3% |
| Jan 2026 | NT$127 million | -38.8% | -74.0% |
| Dec 2025 | NT$488.3 million | -18.0% | +133.5% |
| Nov 2025 | NT$209.1 million | -2.1% | -32.7% |
| Oct 2025 | NT$310.7 million | +36.4% | +75.1% |
| Sep 2025 | NT$177.4 million | -33.3% | -48.5% |
| Aug 2025 | NT$344.7 million | +62.7% | +72.8% |
| Jul 2025 | NT$199.4 million | -19.1% | -22.8% |
| Jun 2025 | NT$258.4 million | -8.7% | -1.6% |
| May 2025 | NT$262.5 million | +3.8% | +15.8% |
| Apr 2025 | NT$226.6 million | +0.1% | -28.0% |
| Mar 2025 | NT$314.6 million | -5.6% | +91.6% |
| Feb 2025 | NT$164.2 million | -44.5% | -20.9% |
| Jan 2025 | NT$207.6 million | -18.3% | -65.1% |
| Dec 2024 | NT$595.1 million | +4.9% | +178.6% |
| Nov 2024 | NT$213.6 million | -28.2% | -6.2% |
| Oct 2024 | NT$227.7 million | -11.8% | -14.4% |
Jan–Oct 2026 cumulative: NT$2.2 billion (-11.0% YoY)
Other Biotech & Medical companies
Compare with peers: SPT vs PEC / SPT vs Lotus Pharm / SPT vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16